Enhanced drug delivery

• US 20050175541A1
• Filed: 11/19/2004
• Published: 08/11/2005
• Est. Priority Date: 11/19/2003
• Status: Abandoned Application

• Current Assignee: Barnes-Jewish Hospital (BJC Health System)
• Original Assignee: Barnes-Jewish Hospital (BJC Health System)
• Inventors: Lanza, Gregory M., Wickline, Samuel A.
• Application Number:
  US10/993,578
• Publication Number:
  US 20050175541A1
• Time in Patent Office: Days
• US Class Current: 424/9.500
• CPC Class Codes: A61K 41/0047 Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
• CPC Class Codes: A61K 47/6909 Micelles formed by phospholipids
• CPC Class Codes: A61K 51/0408 Phospholipids liposomes encapsulating the radioactive probe or having no radiolabelled phospholipids A61K51/1231
• CPC Class Codes: A61K 51/1227 Micelles, e.g. phospholipidic or polymeric micelles
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence

Abstract

The invention is directed to methods for the delivery of a therapeutic agent using lipid-encapsulated particles containing the therapeutic agent and ultrasound energy. For example, it particularly relates to the use of ultrasound with a lipid-encapsulated emulsion comprising an oil where the emulsion is coupled a targeting ligand and comprises a therapeutic agent.

Claims

1. A method for improved delivery of a therapeutic agent to a target,

comprising subjecting a nongaseous, lipid-encapsulated particle comprising a therapeutic agent with ultrasound energy at a frequency and mechanical index that enhances delivery of the agent to the target,

wherein the particle is located at the target, and

wherein the lipid encapsulating said particle is not disrupted during said delivery.

2. The method according to claim 1, wherein the particle comprises at least one fluorocarbon.

3. The method according to claim 2, wherein the fluorocarbon is perfluorooctane, perfluorooctylbromide, or perfluorodichlorooctane.

4. The method according to claim 1, wherein the targeting ligand is a polypeptide, a peptidomimetic, a polysaccharide, a lipid or a nucleic acid.

5. The method according to claim 4, wherein the polypeptide is at least a portion of an antibody.

6. The method according to claim 1, wherein the target resides in a mammalian subject.

7. The method according to claim 6, wherein the subject is human.

8. The method of claim 6, wherein said subject is diagnosed with a disease or condition and said therapeutic agent is selected as appropriate to said disease or condition.

9. The method of claim 1, wherein the particle is coupled to a targeting ligand.